0 XP   0   0   0

Egetis Therapeutics AB (publ)










Financial Health of Egetis




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Egetis Therapeutics AB (publ)
Buy, Hold or Sell?

Should you buy, hold or sell Egetis?

I guess you are interested in Egetis Therapeutics AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Egetis

Let's start. I'm going to help you getting a better view of Egetis Therapeutics AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Egetis Therapeutics AB (publ) even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Egetis Therapeutics AB (publ) is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Egetis Therapeutics AB (publ). The closing price on 2022-12-07 was kr4.08 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Egetis Therapeutics AB (publ) Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Egetis Therapeutics AB (publ).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Egetis earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • A Net Profit Margin of -1,056.9% means that kr-10.57 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Egetis Therapeutics AB (publ):

  • The MRQ is -1,056.9%. The company is making a huge loss. -2
  • The TTM is -764.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-1,056.9%TTM-764.9%-292.0%
TTM-764.9%YOY-638.0%-126.9%
TTM-764.9%5Y-577.7%-187.2%
5Y-577.7%10Y-288.9%-288.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,056.9%-223.6%-833.3%
TTM-764.9%-281.7%-483.2%
YOY-638.0%-344.8%-293.2%
5Y-577.7%-450.1%-127.6%
10Y-288.9%-541.0%+252.1%
1.1.2. Return on Assets

Shows how efficient Egetis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • -8.7% Return on Assets means that Egetis generated kr-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Egetis Therapeutics AB (publ):

  • The MRQ is -8.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-6.0%-2.7%
TTM-6.0%YOY-4.4%-1.6%
TTM-6.0%5Y-7.8%+1.8%
5Y-7.8%10Y-11.4%+3.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-9.9%+1.2%
TTM-6.0%-8.9%+2.9%
YOY-4.4%-9.3%+4.9%
5Y-7.8%-11.7%+3.9%
10Y-11.4%-12.7%+1.3%
1.1.3. Return on Equity

Shows how efficient Egetis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • -9.3% Return on Equity means Egetis generated kr-0.09 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Egetis Therapeutics AB (publ):

  • The MRQ is -9.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.3%TTM-6.4%-2.8%
TTM-6.4%YOY-6.3%-0.1%
TTM-6.4%5Y-8.9%+2.5%
5Y-8.9%10Y-13.1%+4.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.3%-12.0%+2.7%
TTM-6.4%-11.5%+5.1%
YOY-6.3%-10.8%+4.5%
5Y-8.9%-14.2%+5.3%
10Y-13.1%-15.2%+2.1%

1.2. Operating Efficiency of Egetis Therapeutics AB (publ).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Egetis is operating .

  • Measures how much profit Egetis makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • An Operating Margin of -1,025.5% means the company generated kr-10.25  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Egetis Therapeutics AB (publ):

  • The MRQ is -1,025.5%. The company is operating very inefficient. -2
  • The TTM is -785.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-1,025.5%TTM-785.1%-240.4%
TTM-785.1%YOY-622.6%-162.5%
TTM-785.1%5Y-418.5%-366.6%
5Y-418.5%10Y-209.3%-209.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1,025.5%-207.3%-818.2%
TTM-785.1%-271.0%-514.1%
YOY-622.6%-325.9%-296.7%
5Y-418.5%-454.0%+35.5%
10Y-209.3%-537.1%+327.8%
1.2.2. Operating Ratio

Measures how efficient Egetis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 11.86 means that the operating costs are kr11.86 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 11.863. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.757. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ11.863TTM10.757+1.106
TTM10.757YOY7.161+3.595
TTM10.7575Y7.404+3.353
5Y7.40410Y3.702+3.702
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.8632.871+8.992
TTM10.7573.504+7.253
YOY7.1613.604+3.557
5Y7.4045.132+2.272
10Y3.7026.371-2.669

1.3. Liquidity of Egetis Therapeutics AB (publ).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Egetis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.23 means the company has kr6.23 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 6.233. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.047. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.233TTM6.047+0.186
TTM6.047YOY4.572+1.475
TTM6.0475Y10.375-4.328
5Y10.37510Y14.371-3.996
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.2335.117+1.116
TTM6.0475.755+0.292
YOY4.5725.854-1.282
5Y10.3756.511+3.864
10Y14.3716.222+8.149
1.3.2. Quick Ratio

Measures if Egetis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • A Quick Ratio of 6.10 means the company can pay off kr6.10 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 6.095. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.977. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.095TTM4.977+1.118
TTM4.977YOY4.502+0.475
TTM4.9775Y9.945-4.968
5Y9.94510Y13.906-3.961
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0954.284+1.811
TTM4.9774.664+0.313
YOY4.5024.787-0.285
5Y9.9455.218+4.727
10Y13.9065.182+8.724

1.4. Solvency of Egetis Therapeutics AB (publ).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Egetis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Egetis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.06 means that Egetis assets are financed with 5.7% credit (debt) and the remaining percentage (100% - 5.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 0.057. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.059. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.057TTM0.059-0.003
TTM0.059YOY0.293-0.234
TTM0.0595Y0.123-0.064
5Y0.12310Y0.107+0.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0570.278-0.221
TTM0.0590.277-0.218
YOY0.2930.306-0.013
5Y0.1230.367-0.244
10Y0.1070.403-0.296
1.4.2. Debt to Equity Ratio

Measures if Egetis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Egetis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 6.0% means that company has kr0.06 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 0.060. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.063. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.060TTM0.063-0.003
TTM0.063YOY0.415-0.351
TTM0.0635Y0.154-0.091
5Y0.15410Y0.131+0.024
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0600.315-0.255
TTM0.0630.317-0.254
YOY0.4150.319+0.096
5Y0.1540.403-0.249
10Y0.1310.462-0.331

2. Market Valuation of Egetis Therapeutics AB (publ)

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Egetis generates.

  • Above 15 is considered overpriced but always compare Egetis to the Biotechnology industry mean.
  • A PE ratio of -13.22 means the investor is paying kr-13.22 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Egetis Therapeutics AB (publ):

  • The EOD is -16.243. Company is losing money. -2
  • The MRQ is -13.218. Company is losing money. -2
  • The TTM is -30.642. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-16.243MRQ-13.218-3.026
MRQ-13.218TTM-30.642+17.425
TTM-30.642YOY-45.212+14.570
TTM-30.6425Y-70.250+39.608
5Y-70.25010Y-303.273+233.022
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.243-8.986-7.257
MRQ-13.218-9.792-3.426
TTM-30.642-16.243-14.399
YOY-45.212-20.876-24.336
5Y-70.250-16.665-53.585
10Y-303.273-14.732-288.541
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Egetis.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 34.491. Seems overpriced? -1
  • The TTM is 711.789. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ34.491TTM711.789-677.299
TTM711.789YOY-5.280+717.069
TTM711.7895Y262.054+449.735
5Y262.05410Y-73,396.664+73,658.718
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.491-0.032+34.523
TTM711.7890.004+711.785
YOY-5.2800.016-5.296
5Y262.0540.006+262.048
10Y-73,396.6640.003-73,396.667

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Egetis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.22 means the investor is paying kr1.22 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Egetis Therapeutics AB (publ):

  • The EOD is 1.503. Good. +1
  • The MRQ is 1.223. Good. +1
  • The TTM is 1.806. Good. +1
Trends
Current periodCompared to+/- 
EOD1.503MRQ1.223+0.280
MRQ1.223TTM1.806-0.583
TTM1.806YOY2.273-0.467
TTM1.8065Y8.290-6.484
5Y8.29010Y58.277-49.987
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.5031.835-0.332
MRQ1.2232.006-0.783
TTM1.8062.774-0.968
YOY2.2733.453-1.180
5Y8.2902.713+5.577
10Y58.2772.402+55.875
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Egetis Therapeutics AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.2440.033-843%0.481-151%0.058-523%0.061-502%
Book Value Growth--0.8950.904-1%0.919-3%0.902-1%0.901-1%
Book Value Per Share--2.7152.614+4%2.762-2%1.745+56%1.139+138%
Book Value Per Share Growth---0.0900.004-2326%0.161-156%-0.016-83%-0.031-66%
Current Ratio--6.2336.047+3%4.572+36%10.375-40%14.371-57%
Debt To Asset Ratio--0.0570.059-4%0.293-81%0.123-54%0.107-47%
Debt To Equity Ratio--0.0600.063-5%0.415-86%0.154-61%0.131-54%
Dividend Per Share----0%-0%-0%-0%
Eps---0.251-0.168-33%-0.177-30%-0.135-46%-0.093-63%
Eps Growth---0.383-0.184-52%0.580-166%0.153-351%0.064-696%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Net Profit Margin---10.569-7.649-28%-6.380-40%-5.777-45%-2.889-73%
Operating Margin---10.255-7.851-23%-6.226-39%-4.185-59%-2.093-80%
Operating Ratio--11.86310.757+10%7.161+66%7.404+60%3.702+220%
Pb Ratio1.503+19%1.2231.806-32%2.273-46%8.290-85%58.277-98%
Pe Ratio-16.243-23%-13.218-30.642+132%-45.212+242%-70.250+431%-303.273+2194%
Peg Ratio--34.491711.789-95%-5.280+115%262.054-87%-73396.664+212902%
Price Per Share4.080+19%3.3204.585-28%6.288-47%10.773-69%17.138-81%
Price To Total Gains Ratio-16.718-23%-13.604-24.833+83%-39.656+192%-58.513+330%-247.979+1723%
Profit Growth---94.060-92.146-2%-84.789-10%-79.863-15%-85.232-9%
Quick Ratio--6.0954.977+22%4.502+35%9.945-39%13.906-56%
Return On Assets---0.087-0.060-31%-0.044-49%-0.078-11%-0.114+31%
Return On Equity---0.093-0.064-31%-0.063-32%-0.089-4%-0.131+41%
Revenue Growth--0.9120.884+3%0.856+7%0.732+25%0.732+25%
Total Gains Per Share---0.2440.033-843%0.481-151%0.058-523%0.061-502%
Total Gains Per Share Growth---3.595-0.652-82%-6.344+76%-1.343-63%-1.587-56%
Usd Book Value--56104380.00054016379.325+4%57080669.400-2%36070388.010+56%23528942.888+138%
Usd Book Value Change Per Share---0.0240.003-843%0.046-151%0.006-523%0.006-502%
Usd Book Value Per Share--0.2610.252+4%0.266-2%0.168+56%0.110+138%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.024-0.016-33%-0.017-30%-0.013-46%-0.009-63%
Usd Price Per Share0.393+19%0.3200.442-28%0.605-47%1.037-69%1.650-81%
Usd Profit---5190570.000-3474792.900-33%-3649312.575-30%-2783902.995-46%-1922126.333-63%
Usd Revenue--491130.000483257.475+2%961098.075-49%1059901.875-54%529950.938-7%
Usd Total Gains Per Share---0.0240.003-843%0.046-151%0.006-523%0.006-502%
 EOD+2 -3MRQTTM+13 -19YOY+9 -235Y+10 -2210Y+11 -21

3.2. Fundamental Score

Let's check the fundamental score of Egetis Therapeutics AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.243
Price to Book Ratio (EOD)Between0-11.503
Net Profit Margin (MRQ)Greater than0-10.569
Operating Margin (MRQ)Greater than0-10.255
Quick Ratio (MRQ)Greater than16.095
Current Ratio (MRQ)Greater than16.233
Debt to Asset Ratio (MRQ)Less than10.057
Debt to Equity Ratio (MRQ)Less than10.060
Return on Equity (MRQ)Greater than0.15-0.093
Return on Assets (MRQ)Greater than0.05-0.087
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Egetis Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.100
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets617,600
Total Liabilities35,000
Total Stockholder Equity582,600
 As reported
Total Liabilities 35,000
Total Stockholder Equity+ 582,600
Total Assets = 617,600

Assets

Total Assets617,600
Total Current Assets203,200
Long-term Assets203,200
Total Current Assets
Cash And Cash Equivalents 190,100
Net Receivables 8,600
Inventory 800
Total Current Assets  (as reported)203,200
Total Current Assets  (calculated)199,500
+/- 3,700
Long-term Assets
Property Plant Equipment 3,000
Intangible Assets 410,500
Long-term Assets Other 900
Long-term Assets  (as reported)414,400
Long-term Assets  (calculated)414,400
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities32,600
Long-term Liabilities2,400
Total Stockholder Equity582,600
Total Current Liabilities
Accounts payable 7,000
Other Current Liabilities 25,600
Total Current Liabilities  (as reported)32,600
Total Current Liabilities  (calculated)32,600
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,500
Other Liabilities 900
Long-term Liabilities  (as reported)2,400
Long-term Liabilities  (calculated)2,400
+/-0
Total Stockholder Equity
Common Stock11,300
Retained Earnings -861,700
Other Stockholders Equity 1,433,000
Total Stockholder Equity (as reported)582,600
Total Stockholder Equity (calculated)582,600
+/-0
Other
Capital Stock11,300
Cash and Short Term Investments 190,100
Common Stock Shares Outstanding 214,589
Liabilities and Stockholders Equity 617,600
Net Debt -188,600
Net Invested Capital 582,600
Net Tangible Assets 576,900
Net Working Capital 170,600
Short Long Term Debt Total 1,500



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
> Total Assets 
0
0
0
8,492
12,072
118,243
115,023
91,425
82,357
71,630
67,501
60,457
50,445
61,325
56,928
51,011
42,612
51,052
44,229
103,468
88,452
73,889
62,523
52,361
44,668
41,224
26,040
396,435
386,618
368,003
357,230
315,368
300,048
281,121
254,241
242,037
266,050
324,370
291,276
270,073
234,104
193,204
164,000
893,967
850,758
831,510
777,377
569,269
534,822
661,117
617,600
617,600661,117534,822569,269777,377831,510850,758893,967164,000193,204234,104270,073291,276324,370266,050242,037254,241281,121300,048315,368357,230368,003386,618396,43526,04041,22444,66852,36162,52373,88988,452103,46844,22951,05242,61251,01156,92861,32550,44560,45767,50171,63082,35791,425115,023118,24312,0728,492000
   > Total Current Assets 
0
0
0
797
2,583
106,376
97,917
91,413
82,296
71,571
67,442
60,399
50,389
61,269
56,873
50,956
42,557
50,998
44,176
103,416
88,400
73,837
62,472
52,361
44,668
41,224
26,040
396,435
386,618
368,003
357,230
315,368
300,048
281,121
254,241
242,037
265,767
324,140
291,100
269,950
233,912
193,069
163,918
299,871
257,031
237,678
183,428
152,902
119,129
246,098
203,200
203,200246,098119,129152,902183,428237,678257,031299,871163,918193,069233,912269,950291,100324,140265,767242,037254,241281,121300,048315,368357,230368,003386,618396,43526,04041,22444,66852,36162,47273,83788,400103,41644,17650,99842,55750,95656,87361,26950,38960,39967,44271,57182,29691,41397,917106,3762,583797000
       Cash And Cash Equivalents 
0
0
0
568
2,334
106,165
97,659
90,548
81,646
68,608
65,487
58,808
48,264
59,116
54,910
49,302
41,388
47,799
40,675
100,043
86,070
69,586
59,313
50,360
43,684
31,666
23,590
393,998
382,041
363,748
354,342
309,531
294,342
267,053
250,267
229,876
258,036
319,549
286,748
255,101
221,141
184,470
159,424
287,850
249,775
207,411
173,150
143,965
106,785
233,216
190,100
190,100233,216106,785143,965173,150207,411249,775287,850159,424184,470221,141255,101286,748319,549258,036229,876250,267267,053294,342309,531354,342363,748382,041393,99823,59031,66643,68450,36059,31369,58686,070100,04340,67547,79941,38849,30254,91059,11648,26458,80865,48768,60881,64690,54897,659106,1652,334568000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,200
3,564
7,052
1,274
7,459
3,811
27,531
6,687
6,945
6,141
7,551
8,600
8,6007,5516,1416,9456,68727,5313,8117,4591,2747,0523,5645,200000000000000000000000000000000000000000
       Other Current Assets 
0
0
0
229
249
211
258
866
650
2,963
1,955
1,591
2,125
2,153
1,963
1,654
1,169
3,199
3,501
3,373
2,330
4,251
3,159
2,001
984
9,558
2,450
2,437
4,577
4,255
2,888
5,837
5,706
14,068
3,974
12,161
7,731
4,591
4,352
14,849
12,771
8,599
4,494
8,883
5,182
28,630
9,314
-1
11,904
12,651
12,300
12,30012,65111,904-19,31428,6305,1828,8834,4948,59912,77114,8494,3524,5917,73112,1613,97414,0685,7065,8372,8884,2554,5772,4372,4509,5589842,0013,1594,2512,3303,3733,5013,1991,1691,6541,9632,1532,1251,5911,9552,963650866258211249229000
   > Long-term Assets 
0
0
0
7,695
9,489
11,867
17,105
12
61
59
59
57
57
56
56
55
54
54
53
52
52
52
51
0
0
0
0
0
0
0
0
0
0
0
0
0
283
230
176
123
193
134
81
594,097
593,727
593,832
593,949
416,366
415,693
415,020
414,400
414,400415,020415,693416,366593,949593,832593,727594,0978113419312317623028300000000000005152525253545455565657575959611217,10511,8679,4897,695000
       Property Plant Equipment 
0
0
0
4
15
14
13
12
11
10
9
8
7
6
6
5
4
4
3
3
2
2
1
1
0
0
0
0
0
0
0
0
0
0
0
0
283
230
176
123
193
134
81
4,741
4,642
5,019
4,620
4,275
3,872
3,470
3,000
3,0003,4703,8724,2754,6205,0194,6424,74181134193123176230283000000000000112233445667891011121314154000
       Intangible Assets 
0
0
0
7,691
9,474
11,853
17,092
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
589,356
589,085
588,815
588,544
411,307
411,036
410,766
410,500
410,500410,766411,036411,307588,544588,815589,085589,35600000000000000000000000000000000000017,09211,8539,4747,691000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
115
0
0
0
0
109
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
269
163
581,784
581,784
581,782
581,784
404,817
404,817
404,815
404,900
404,900404,815404,817404,817581,784581,782581,784581,784163269-100000000000000000000000109000011500000000000
> Total Liabilities 
0
0
0
1,502
908
5,194
2,065
3,893
4,102
3,924
5,437
6,516
4,535
2,903
3,014
4,057
2,434
3,367
7,810
12,810
9,945
5,615
5,680
4,329
3,481
12,021
4,769
6,873
9,337
5,586
21,957
11,657
12,148
21,432
12,742
22,675
23,598
24,595
23,394
25,197
32,047
27,209
22,567
264,340
240,249
255,104
222,967
42,230
35,761
26,146
35,000
35,00026,14635,76142,230222,967255,104240,249264,34022,56727,20932,04725,19723,39424,59523,59822,67512,74221,43212,14811,65721,9575,5869,3376,8734,76912,0213,4814,3295,6805,6159,94512,8107,8103,3672,4344,0573,0142,9034,5356,5165,4373,9244,1023,8932,0655,1949081,502000
   > Total Current Liabilities 
0
0
0
1,502
908
5,194
2,065
3,893
4,102
3,924
5,436
6,516
4,536
2,903
3,015
4,057
2,434
3,368
7,810
12,810
9,945
5,615
5,680
4,329
3,481
12,020
4,769
6,874
9,337
5,586
21,958
11,657
12,148
21,432
12,742
22,675
23,482
24,478
23,277
25,081
32,018
27,174
22,481
70,141
49,419
67,153
34,800
39,170
32,959
23,583
32,600
32,60023,58332,95939,17034,80067,15349,41970,14122,48127,17432,01825,08123,27724,47823,48222,67512,74221,43212,14811,65721,9585,5869,3376,8744,76912,0203,4814,3295,6805,6159,94512,8107,8103,3682,4344,0573,0152,9034,5366,5165,4363,9244,1023,8932,0655,1949081,502000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,141
1,297
1,473
0
0
0
1,532
0
01,5320001,4731,2971,1410000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
1,021
377
730
737
1,432
1,730
2,003
2,766
2,331
984
809
434
1,278
189
1,521
4,782
9,967
5,102
2,507
2,481
1,766
1,102
9,449
2,271
4,678
6,022
3,538
19,023
5,972
6,018
15,652
6,814
15,174
16,835
14,476
2,909
11,207
13,264
10,089
3,904
15,611
3,716
34,751
8,795
4,596
5,692
4,912
7,000
7,0004,9125,6924,5968,79534,7513,71615,6113,90410,08913,26411,2072,90914,47616,83515,1746,81415,6526,0185,97219,0233,5386,0224,6782,2719,4491,1021,7662,4812,5075,1029,9674,7821,5211891,2784348099842,3312,7662,0031,7301,4327377303771,021000
       Other Current Liabilities 
0
0
0
482
531
4,464
1,328
2,462
2,372
1,921
2,670
4,185
3,552
2,094
2,581
2,779
2,245
1,847
3,028
2,843
4,843
3,108
3,199
2,563
2,379
2,571
2,498
2,196
3,315
2,048
2,935
5,685
6,130
5,780
5,928
7,501
6,647
10,002
20,368
13,874
18,754
17,085
18,577
53,389
44,406
30,929
26,005
27,714
27,267
17,139
25,600
25,60017,13927,26727,71426,00530,92944,40653,38918,57717,08518,75413,87420,36810,0026,6477,5015,9285,7806,1305,6852,9352,0483,3152,1962,4982,5712,3792,5633,1993,1084,8432,8433,0281,8472,2452,7792,5812,0943,5524,1852,6701,9212,3722,4621,3284,464531482000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
1
0
-1
0
-1
0
0
-1
0
0
0
0
0
0
0
1
0
-1
0
0
-1
0
0
0
0
0
116
117
117
116
29
35
86
194,199
190,830
187,951
188,167
3,060
2,802
2,563
2,400
2,4002,5632,8023,060188,167187,951190,830194,19986352911611711711600000-100-1010000000-100-10-1010000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
86
190,673
187,609
184,542
185,262
410
537
686
900
900686537410185,262184,542187,609190,673863500000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
581,784
581,784
581,784
581,784
404,817
404,817
404,817
404,800
404,800404,817404,817404,817581,784581,784581,784581,7840000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
6,990
11,165
113,050
112,957
87,532
78,255
67,706
62,064
53,941
45,910
58,422
53,913
46,953
40,177
47,684
36,419
90,658
78,507
68,274
56,843
48,032
41,186
29,203
21,271
389,562
377,281
362,416
335,272
303,711
287,900
259,688
241,498
219,361
242,452
299,775
267,883
244,876
202,058
165,995
141,433
629,627
610,509
576,407
554,411
527,038
499,061
634,972
582,600
582,600634,972499,061527,038554,411576,407610,509629,627141,433165,995202,058244,876267,883299,775242,452219,361241,498259,688287,900303,711335,272362,416377,281389,56221,27129,20341,18648,03256,84368,27478,50790,65836,41947,68440,17746,95353,91358,42245,91053,94162,06467,70678,25587,532112,957113,05011,1656,990000
   Common Stock
0
0
0
301
696
696
1,066
1,066
1,066
1,066
1,066
1,066
1,066
1,154
1,154
1,154
1,154
1,243
1,243
1,492
1,492
1,494
1,494
1,494
1,494
1,494
1,494
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,818
2,818
2,818
2,818
2,818
2,818
8,688
8,688
8,688
8,688
8,688
8,688
11,294
11,300
11,30011,2948,6888,6888,6888,6888,6888,6882,8182,8182,8182,8182,8182,8182,5612,5612,5612,5612,5612,5612,5612,5612,5612,5611,4941,4941,4941,4941,4941,4941,4921,4921,2431,2431,1541,1541,1541,1541,0661,0661,0661,0661,0661,0661,066696696301000
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000000000000000000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,489
13,316
117,689
119,712
119,712
86,466
86,465
86,465
86,732
52,876
71,347
71,347
71,348
45,798
65,890
65,890
137,586
89,166
90,374
90,374
90,374
46,538
46,538
46,538
425,224
387,001
388,325
388,518
617,944
617,944
617,944
618,598
618,597
618,600
705,027
705,278
705,278
705,278
705,387
705,551
1,263,285
1,263,482
1,263,705
1,264,239
1,306
1,264,982
1,431,530
1,433,000
1,433,0001,431,5301,264,9821,3061,264,2391,263,7051,263,4821,263,285705,551705,387705,278705,278705,278705,027618,600618,597618,598617,944617,944617,944388,518388,325387,001425,22446,53846,53846,53890,37490,37490,37489,166137,58665,89065,89045,79871,34871,34771,34752,87686,73286,46586,46586,466119,712119,712117,68913,31610,489000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue38,243
Cost of Revenue-96,527
Gross Profit-58,284-58,284
 
Operating Income (+$)
Gross Profit-58,284
Operating Expense-46,799
Operating Income-105,681-105,083
 
Operating Expense (+$)
Research Development-
Selling General Administrative14,513
Selling And Marketing Expenses-
Operating Expense46,79914,513
 
Net Interest Income (+$)
Interest Income106
Interest Expense-188
Net Interest Income-82-82
 
Pretax Income (+$)
Operating Income-105,681
Net Interest Income-82
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-104,542-106,820
EBIT - interestExpense = -104,542
-104,542
-104,354
Interest Expense188
Earnings Before Interest and Taxes (ebit)-104,354-104,354
Earnings Before Interest and Taxes (ebitda)-101,899
 
After tax Income (+$)
Income Before Tax-104,542
Tax Provision-0
Net Income From Continuing Ops-104,542-104,542
Net Income-104,542
Net Income Applicable To Common Shares-104,542
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses143,326
Total Other Income/Expenses Net1,13982
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
LIKE.CC
1 minute ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of LIKE.CC.

LIKE.CC Daily Candlestick Chart
LBK.CC
2 minutes ago

I found you a STOCH Bullish Reversal Divergence on the daily chart of LBK.CC.

LBK.CC Daily Candlestick Chart
JOINT.CC
7 minutes ago

I found you a Death Cross on the daily chart of JOINT.CC.

JOINT.CC Daily Candlestick Chart
ION.CC
10 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ION.CC.

ION.CC Daily Candlestick Chart
RV.V
16 minutes ago

I found you a STOCH Bearish Hidden Divergence on the daily chart of RV.V.

RV.V Daily Candlestick Chart
SCL.TO
18 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of SCL.TO.

SCL.TO Daily Candlestick Chart
PRU.TO
23 minutes ago

I found you a MACD Bullish Hidden Divergence on the daily chart of PRU.TO.

PRU.TO Daily Candlestick Chart
XSQ.TO
29 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of XSQ.TO.

XSQ.TO Daily Candlestick Chart
NA.TO
31 minutes ago

I found you a Golden Cross on the daily chart of NA.TO.

NA.TO Daily Candlestick Chart
MNT.TO
32 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MNT.TO.

MNT.TO Daily Candlestick Chart
MOGO.TO
32 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of MOGO.TO.

MOGO.TO Daily Candlestick Chart
L.TO
37 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of L.TO.

L.TO Daily Candlestick Chart
HZD.TO
40 minutes ago

I found you a Death Cross on the daily chart of HZD.TO.

HZD.TO Daily Candlestick Chart
TLGN.PINK
44 minutes ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of TLGN.PINK.

TLGN.PINK Daily Candlestick Chart
GXE.TO
45 minutes ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GXE.TO.

GXE.TO Daily Candlestick Chart
NHK.TO
48 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of NHK.TO.

NHK.TO Daily Candlestick Chart
ZMU.TO
49 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZMU.TO.

ZMU.TO Daily Candlestick Chart
PNPN.V
51 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of PNPN.V.

PNPN.V Daily Candlestick Chart
TRL.TO
52 minutes ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of TRL.TO.

TRL.TO Daily Candlestick Chart
VBNK.TO
53 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VBNK.TO.

VBNK.TO Daily Candlestick Chart
VCB.TO
56 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VCB.TO.

VCB.TO Daily Candlestick Chart
ZDH.TO
57 minutes ago

I found you a Golden Cross on the daily chart of ZDH.TO.

ZDH.TO Daily Candlestick Chart
MUS.TO
58 minutes ago

I found you a Golden Cross on the daily chart of MUS.TO.

MUS.TO Daily Candlestick Chart
VRIF.TO
59 minutes ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of VRIF.TO.

VRIF.TO Daily Candlestick Chart
ZLC.TO
1 hour ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of ZLC.TO.

ZLC.TO Daily Candlestick Chart